Abstract
Immune thrombocytopenia (ITP), previously referred to in literature and practice as idiopathic thrombocytopenia purpura, is an acquired disorder of immune-mediated destruction of platelets. In the acute setting, the principal goals of treatment are to prevent or stop life-threatening hemorrhage, evaluate for secondary causes, and promptly initiate treatment while monitoring for adverse events. The treatment of chronic ITP has evolved over the last 20 years, and with new therapeutic targets, improving rates of remission with medical therapy alone is possible. Patients with chronic ITP require a multidisciplinary team whose job is to navigate important decisions with regard to treatment and management of the patient’s comorbidities and mitigate the risk of deleterious effects caused by many of these therapies. Surgery remains an important treatment modality in refractory cases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495–520.
Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511–21.
Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11):2377–83.
Wu S-R, Kuo H-C, Huang W-C, et al. Incidence, clinical characteristics, and associated diseases in patients with immune thrombocytopenia: a nationwide population-based study in Taiwan. Thromb Res. 2018;164:90–5.
Lee JY, Lee J-H, Lee H, et al. Epidemiology and management of primary immune thrombocytopenia: a nationwide population-based study in Korea. Thromb Res. 2017;155:86–91.
Khan AM, Mydra H, Nevarez A. Clinical practice updates in the management of immune thrombocytopenia. P T. 2017;42(12):756–63.
Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93.
Dal MS, Karakus A, Dal T, et al. Assessment of the underlying causes of the immune thrombocytopenia: ten years experience. J Pak Med Assoc. 2017;67(7):1004–8.
Liebman H. Other immune thrombocytopenias. Semin Hematol. 2007;44(4 Suppl 5):S24–34.
Reese JA, Li X, Hauben M, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010;116(12):2127–33.
Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.
Cecinati V, Principi N, Brescia L, Giordano P, Esposito S. Vaccine administration and the development of immune thrombocytopenic purpura in children. Hum Vaccin Immunother. 2013;9(5):1158–62.
Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829–35.
Palau J, Jarque I, Sanz MA. Long-term management of chronic immune thrombocytopenic purpura in adults. Int J Gen Med. 2010;3:305–11.
Kojouri K. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623–34.
Katkhouda N, Grant SW, Mavor E, et al. Predictors of response after laparoscopic splenectomy for immune thrombocytopenic purpura. Surg Endosc. 2001;15(5):484–8.
Palandri F, Polverelli N, Sollazzo D, et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016;91(4):E267–72.
Kim DK, Riley LE, Hunter P, on behalf of the Advisory Committee on Immunization Practices. Recommended immunization schedule for adults aged 19 years or older, United States, 2018*. Ann Intern Med. 2018;168(3):210.
Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32(10):875–87.
Chater C, Terriou L, Duhamel A, et al. Reemergence of splenectomy for ITP second-line treatment? Ann Surg. 2016;264(5):772–7.
Morris KT, Horvath KD, Jobe BA, Swanstrom LL. Laparoscopic management of accessory spleens in immune thrombocytopenic purpura. Surg Endosc. 1999;13(5):520–2.
Gigot J-F, Gigot F, Jamar F, et al. Inadequate detection of accessory spleens and splenosis with laparoscopic splenectomy A shortcoming of the laparoscopic approach in hematologic diseases. Surg Endosc. 1998;12(2):101–6.
Moris D, Dimitriou N, Griniatsos J. Laparoscopic splenectomy for benign hematological disorders in adults: a systematic review. In Vivo. 2017;31(3):291–302.
Rattner DW, Ellman L, Warshaw AL. Portal vein thrombosis after elective splenectomy. An underappreciated, potentially lethal syndrome. Arch Surg. 1993;128(5):565–569; discussion 569-570.
Rottenstreich A, Kleinstern G, Spectre G, Da’as N, Ziv E, Kalish Y. Thromboembolic events following splenectomy: risk factors, prevention, management and outcomes. World J Surg. 2018;42(3):675–81.
de’Angelis N, Abdalla S, Lizzi V, et al. Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomy. Surgery. 2017;162(6):1219–30.
Bouvier A, Gout M, Audia S, Chalumeau C, Rat P, Deballon O. Routine screening of splenic or portal vein thrombosis after splenectomy. Rev Med Interne. 2017;38(1):3–7.
Tran T, Demyttenaere SV, Polyhronopoulos G, et al. Recommended timing for surveillance ultrasonography to diagnose portal splenic vein thrombosis after laparoscopic splenectomy. Surg Endosc. 2010;24(7):1670–8.
Brigden ML, Pattullo AL. Prevention and management of overwhelming postsplenectomy infection--an update. Crit Care Med. 1999;27(4):836–42.
Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005;90(1):72–7.
Chang CC, Chang HC, Wu CH, Chang CY, Liao CC, Chen TL. Adverse postoperative outcomes in surgical patients with immune thrombocytopenia. Br J Surg. 2013;100(5):684–692; discussion 693.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bogenberger, K.J., Park, C.W. (2019). Immune Thrombocytopenia: Incidence, Diagnosis, Presentation, and Surgical Management. In: Lim, R. (eds) Multidisciplinary Approaches to Common Surgical Problems. Springer, Cham. https://doi.org/10.1007/978-3-030-12823-4_46
Download citation
DOI: https://doi.org/10.1007/978-3-030-12823-4_46
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-12822-7
Online ISBN: 978-3-030-12823-4
eBook Packages: MedicineMedicine (R0)